Cowen And Company, LLC Apellis Pharmaceuticals, Inc. Transaction History

Cowen And Company, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$37.14 - $64.82 $2.47 Million - $4.31 Million	66,470 New	66,470 $3.98 Million
Q4 2022 Feb 09, 2023	SELL	$43.24 - $61.04 $605,360 - $854,560	-14,000 Reduced 73.68%	5,000 $258,000
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $716,518 - $1.12 Million	16,008 Added 535.03%	19,000 $501,000
Q2 2022 Aug 05, 2022	BUY	$35.07 - $59.21 $61,793 - $104,328	1,762 Added 143.25%	2,992 $135,000
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $43,615 - $66,567	1,230 New	1,230 $62,000
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.78 Million - $2.85 Million	-57,889 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $1.57 Million - $3.5 Million	50,133 Added 646.38%	57,889 $1.91 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $317,220 - $503,364	7,756 New	7,756 $490,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.